Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
Skip navigation

A trial looking at treatment for high risk chronic lymphocytic leukaemia (CLL 210)

This trial is looking at a new combination of treatment for high risk chronic lymphocytic leukaemia (CLL). High risk CLL is more difficult to treat and more likely to come back after treatment. This trial is supported by Cancer Research UK.

Doctors often treat chronic lymphocytic leukaemia (CLL) with chemotherapy or biological therapy. This can work well and there is no sign of the leukaemia (it goes into remission). But sometimes it doesn’t work very well and doctors are keen to improve treatment so that more people go into remission.

Some leukaemia cells have a faulty (mutated) or missing gene called p53. If the cells have this fault, the leukaemia is classed as high risk.

There are 2 parts to this trial. The first part is looking at a new combination of 3 drugs known as ROD (Revlimid, ofatumumab, dexamethasone). This is called induction therapy and the aim is for the leukaemia to go into remission. The drugs are

Please note people who agreed to take part in this trial before 11th September 2012 had the following combination of drugs alemtuzumab, dexamethasone and lenalidomide (CamDexRev).   

The second part of the trial is looking at the longer term use of lenalidomide. This is called maintenance therapy and the aim is for the leukaemia to stay in remission for as long as possible. About half the people who join this part of the trial will have lenalidomide, the other half won’t.

The aims of this trial are to find out

  • How well ROD works as induction therapy for high risk chronic lymphocytic leukaemia
  • How well lenalidomide works as a maintenance therapy
  • More about the side effects
  • How these treatments affect quality of life

Recruitment

Start 06/02/2012
End 01/07/2015

Phase

Phase 2

Who can enter

You may be able to take part in this trial if you have chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that is classed as high risk. SLL is almost the same as CLL. High risk means either

  • You have CLL or SLL that didn’t go into remission with treatment containing fludarabine, or
  • You have CLL or SLL that has come back within a year of having treatment containing fludarabine, or
  • At least 1 in 5 (20%) of your leukaemia cells have a faulty or missing p53 gene

As well as that, you must

  • Have satisfactory blood test results
  • Be well enough to be up and about for at least half the day (performance status 0, 1 or 2)
  • Be prepared to use reliable contraception

You cannot enter this trial if you

  • Have leukaemia or lymphoma in your brain or spinal cord
  • Have had ofatumumab or lenalidomide before
  • Have already had more than 3 treatments for your CLL
  • Have had steroids for your CLL before and they didn’t work
  • Have had surgery in the last 4 weeks
  • Have taken part in another clinical trial in the last 4 weeks
  • Have an infection
  • Have inflammation of the stomach or a stomach ulcer
  • Have diabetes or high blood pressure
  • Have had blood clots in the past
  • Have got Hepatitis B, Hepatitis C or HIV
  • Have CLL that has changed into a fast growing diffuse B cell lymphoma (this is called Richter’s transformation)
  • Have had any other cancer in the last 5 years, apart from non melanoma skin cancer that was successfully treated
  • Have any other serious medical condition
  • Are pregnant or breastfeeding

Trial design

This is a phase 2 trial that will now recruit 101 people with high risk CLL or SLL.

People recruited before 11th September 2012 had the monoclonal antibody alemtuzumab instead of ofatumumab. The researchers decided to change to ofatumumab because it became difficult to get alemtuzumab from the manufacturers. They expect the combination of lenalidomide, ofatumumab and dexamethasone (ROD) to work just as well as alemtuzumab, dexamethasone and lenalidomide (CamDexRev). They also expect it to have fewer side effects.  

When the combination was changed 16 people had been recruited to have CamDexRev. The trial will recruit another 85 people to have ROD. This will make a total 101 people recruited into this trial.  

Everyone taking part has ROD induction therapy for the first 6 months. During that time you

  • Take dexamethasone tablets for a few days each week for 4 months
  • Take lenalidomide capsules every day for 5 months
  • Have ofatumumab as an injection into the vein once a week for 8 weeks then once a fortnight for 8 weeks

After this the doctors will look to see how well the treatment has worked. What happens next will depend on the results.

If the treatment has not worked very well you will stop being part of the trial and continue to see your own doctor for treatment.

If the treatment has worked well and you are suitable, you will be offered a bone marrow or stem cell transplant.

If the treatment has worked well and do not have a bone marrow or stem cell transplant, you will join the next part of the trial.

The next part of the trial is randomised. This means that you are put into a treatment group by a computer and have an equal chance of being in either treatment group. Neither you nor your doctor will be able to decide which group you are in.

Group 1 don’t have any further treatment.

Group 2 take lenalidomide every day until the leukaemia starts to grow again. This is called maintenance treatment and the aim is to delay the leukaemia growing again.

Hospital visits

You see the doctors and have some tests before you can take part in this trial. These tests include

The treatments in this trial are either tablets or injections you have into the skin. So you should be able to have treatment as an out patient or at home.

You have blood tests regularly during the trial. You have a CT scan and bone marrow test about 6 months and 2½ years after joining the trial.

If you take part in the randomised part of the trial, you will go to the hospital every 2 weeks to begin with. But you gradually go less often.  After your treatment has finished, you will see the trial doctors every 2 months.

You fill out a questionnaire before you start treatment and then 6 times during the trial. It will ask about side effects and how you’ve been feeling. This is called a quality of life questionnaire.

Side effects

As with all treatments, those used in this trial have some side effects. The most common side effects of dexamethasone are

  • Indigestion or heartburn
  • Water retention causing swollen hands or feet
  • Increase in blood sugar levels
  • Changes in mood or behaviour
  • Increased blood pressure
  • Increased risk of infection

The most common side effects of ofatumumab are

  • A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
  • Pain, swelling or redness at the injection site
  • Infection

The most common side effects of lenalidomide include

  • A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
  • Tiredness
  • Muscle cramps and pain
  • Dizziness
  • Rash

Lenalidomide can cause birth defects in children. So you must not become pregnant or father a child while taking it.

There is more information about side effects of dexamethasone, ofatumumab and lenalidomide in our cancer drugs section.

Location of trial

For more information

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.

Find out how to join a trial or contact our cancer information nurses for other questions about cancer by phone (0808 800 4040), by email, or at

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Chief Investigator

Prof A Pettitt

This is Cancer Research UK trial number CRUKE/09/035.

Supported by

Baxter Ltd
Cancer Research UK
Cancer Research UK Liverpool Cancer Trials Unit (LCTU)
Celgene Ltd
Chugai Pharmaceutical Co Ltd
GlaxoSmithKline (GSK)
National Institute for Health Research Cancer Research Network (NCRN)
Royal Liverpool and Broadgreen University Hospital NHS Trust
University of Liverpool
Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 13 February 2014